Availability, Price, and Affordability of Diabetes Mellitus and Thyroid Dysfunction Medicines in South Wollo Zone, Northeast Ethiopia

Overview

Journal BMC Health Serv Res

Publisher Biomed Central

Specialty Health Services

Date 2024 Nov 20

PMID 39563385

Authors

Solomon Ahmed Mohammed

Haile Yirga Mengesha

Abel Andualem

Elham Seid

Getnet Mengistu Assefa

Affiliations

Soon will be listed here.

Abstract

Background: Diabetes mellitus and thyroid dysfunction are prevalent endocrine disorders that impose enormous burdens on patients and countries. However, access to essential medicines remains inadequate in many low-income countries. This study evaluated medications' availability, price, and affordability for these conditions.

Methods: A cross-sectional study was conducted at health facilities in the South Wollo zone in 2022. Following World Health Organization (WHO)/Health Action International (HAI) guidelines, 34 medicines were evaluated across 60 medicine outlets. Data were collected using a standardized tool adapted from WHO/HAI. Availability was measured by the percentage of facilities where the medicines were in stock. Prices were reported as median prices and median price ratios (MPR). Affordability was assessed based on the number of days' wages required for the lowest-paid government workers to cover the full course of therapy.

Results: The availability of lowest-priced generic (LPG) diabetes and thyroid dysfunction medicines in the public sector was 24.4% and 28.7%, respectively. In private pharmacies, availability was 26.3% for diabetes and 21% for thyroid dysfunction medicines. Median prices for LPG medicines were higher in private pharmacies than in public health facilities, with 81.81% showing a statistically significant difference (p < 0.05). In private pharmacies, the prices of LPG diabetes (5, 71.43%) and thyroid dysfunction medicines (5, 83.33%) exceeded the reference price. None of the LPG diabetes and thyroid dysfunction medicines were affordable in either setting.

Conclusions: The study revealed a very low availability of medicines and a financial burden on patients. Therefore, the government should improve the availability of these essential medicines and regulate their prices.

References

Ewen M, Joosse H, Beran D, Laing R . Insulin prices, availability and affordability in 13 low-income and middle-income countries. BMJ Glob Health. 2019; 4(3):e001410. PMC: 6570978. DOI: 10.1136/bmjgh-2019-001410. View

Yang C, Hu S, Zhu Y, Zhu W, Li Z, Fang Y . Evaluating access to oral anti-diabetic medicines: A cross-sectional survey of prices, availability and affordability in Shaanxi Province, Western China. PLoS One. 2019; 14(10):e0223769. PMC: 6795464. DOI: 10.1371/journal.pone.0223769. View

Khatib R, Mckee M, Shannon H, Chow C, Rangarajan S, Teo K . Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2015; 387(10013):61-9. DOI: 10.1016/S0140-6736(15)00469-9. View

van Mourik M, Cameron A, Ewen M, Laing R . Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010; 10:25. PMC: 2898673. DOI: 10.1186/1471-2261-10-25. View

Gong S, Cai H, Ding Y, Li W, Juan X, Peng J . The availability, price and affordability of antidiabetic drugs in Hubei province, China. Health Policy Plan. 2018; 33(8):937-947. DOI: 10.1093/heapol/czy076. View

Li Z, Feng Q, Kabba J, Yang C, Chang J, Jiang M . Prices, availability and affordability of insulin products: a cross-sectional survey in Shaanxi Province, western China. Trop Med Int Health. 2018; 24(1):43-52. DOI: 10.1111/tmi.13167. View

Hinsch M, Kaddar M, Schmitt S . Enhancing medicine price transparency through price information mechanisms. Global Health. 2014; 10:34. PMC: 4019947. DOI: 10.1186/1744-8603-10-34. View

Hadgu R, Worede A, Ambachew S . Prevalence of thyroid dysfunction and associated factors among adult type 2 diabetes mellitus patients, 2000-2022: a systematic review and meta-analysis. Syst Rev. 2024; 13(1):119. PMC: 11061916. DOI: 10.1186/s13643-024-02527-y. View

Fralick M, Jenkins A, Khunti K, Mbanya J, Mohan V, Schmidt M . Global accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol. 2022; 18(4):199-204. PMC: 8762447. DOI: 10.1038/s41574-021-00621-y. View

10.

Koster I, von Ferber L, Ihle P, Schubert I, Hauner H . The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study. Diabetologia. 2006; 49(7):1498-504. DOI: 10.1007/s00125-006-0277-5. View

11.

Deressa H, Abuye H, Adinew A, Ali M, Kebede T, Habte B . Access to essential medicines for diabetes care: availability, price, and affordability in central Ethiopia. Glob Health Res Policy. 2024; 9(1):12. PMC: 10999076. DOI: 10.1186/s41256-024-00352-3. View

12.

Ogbera A, Kuku S . Epidemiology of thyroid diseases in Africa. Indian J Endocrinol Metab. 2011; 15(Suppl 2):S82-8. PMC: 3169867. DOI: 10.4103/2230-8210.83331. View

13.

Wang L, Dai L, Liu H, Dai H, Li X, Ge W . Availability, affordability and price components of insulin products in different-level hospital pharmacies: Evidence from two cross-sectional surveys in Nanjing, China. PLoS One. 2021; 16(8):e0255742. PMC: 8360381. DOI: 10.1371/journal.pone.0255742. View

14.

Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J . Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103(2):137-49. DOI: 10.1016/j.diabres.2013.11.002. View

15.

Kaiser A, Hehman L, Forsberg B, Simangolwa W, Sundewall J . Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia. PLoS One. 2019; 14(12):e0226169. PMC: 6910693. DOI: 10.1371/journal.pone.0226169. View

16.

Watkins P, Alemu S . Delivery of diabetes care in rural Ethiopia: an experience from Gondar. Ethiop Med J. 2003; 41(1):9-17. View

17.

Moucheraud C, Lenz C, Latkovic M, Wirtz V . The costs of diabetes treatment in low- and middle-income countries: a systematic review. BMJ Glob Health. 2019; 4(1):e001258. PMC: 6407562. DOI: 10.1136/bmjgh-2018-001258. View

18.

Asmamaw G, Shimelis T, Tewuhibo D, Bitew T, Ayenew W . Access to essential medicines used in the management of noncommunicable diseases in Southern Ethiopia: Analysis using WHO/HAI methodology. SAGE Open Med. 2024; 12:20503121241266318. PMC: 11292716. DOI: 10.1177/20503121241266318. View

19.

Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J . Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87(3):293-301. DOI: 10.1016/j.diabres.2010.01.026. View

20.

Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R . Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2008; 373(9659):240-9. DOI: 10.1016/S0140-6736(08)61762-6. View